InterMune introduces idiopathic pulmonary fibrosis therapy in Canada

University of Toronto professor and vice-chair of medicine and University Health Network IPF researcher and consultant respirologist Charles Chan said, "Esbriet really is a game-changer. I am excited to finally have a treatment option with proven benefits for patients who are living with this deadly and life-limiting disease."

Health Canada previously approved Esbriet (pirfenidone) making it the only approved drug in Canada indicated for IPF treatment.

Esbriet has demonstrated to slow down the disease progression in addition to lessen the lung function declination in adult patients with mild to moderate IPF in earlier studies.

InterMune chairman, chief executive officer and president Daniel Welch said, "Patient access to treatment is a priority for InterMune and we are working diligently with public and private payers and reimbursement agencies to make Esbriet accessible to appropriate Canadian patients who may benefit from this new treatment option."